Caissa Capital Management ltd.'s Form 4 filing
Avalo Therapeutics, Inc. (AVTX) · filed Apr 27, 2023
- Accession no.
- 0001929354-23-000006
- Filed
- Apr 27, 2023
- Trade date
- Apr 25-27, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market purchases total $22.4K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Caissa Capital Management ltd.CIK 0001929354 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 25, 2023 | Common Stock | PPurchaseAcquired | +5,571 | $3.00F2 | +$16,713 | 1,315,771 | Indirect | |
| Apr 26, 2023 | Common Stock | PPurchaseAcquired | +425 | $2.97 | +$1,262.25 | 1,316,196 | Indirect | |
| Apr 27, 2023 | Common Stock | PPurchaseAcquired | +1,504 | $2.96F3 | +$4,451.84 | 1,317,700 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.97 to $3.05, inclusive.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.95 to $2.97, inclusive.
Referenced by the price of 1 transaction in Table I.